Technology
Technology
Celladon scientists, led by company co-founder Roger J. Hajjar, M.D., Director of the Cardiovascular Research Center at Mount Sinai School of Medicine, New York, developed MYDICAR®, a potential breakthrough for the treatment of severe heart failure. MYDICAR is designed to restore a critical enzyme necessary for the heart to pump more efficiently. Read MoreClinical Trials
Clinical Trials
MYDICAR® is currently in Phase 1/2 clinical testing to investigate safety and biological effects of restoring specific enzyme activity. Replacing the enzyme may restore function and reverse heart failure. The Phase 1 portion is an open-label, sequential dose escalation study. The Phase 2 portion is a randomized, double-blind, placebo-controlled, parallel-group, dose ranging trial that compares the use of MYDICAR at two or three dose levels with placebo. This study is currently enrolling patients with advanced heart failure at 15 leading cardiology medical centers across the U.S. Read More| Welcome to Celladon |
| Celladon is a privately held biotechnology company founded with the goal of developing molecular therapies for cardiovascular diseases. Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new technologies have provided the foundation for new, rational, and technologically sophisticated approaches to cardiovascular treatments. Our first product candidate is designed to target the key enzyme deficiency in advanced heart failure which regulates calcium cycling and contractility in heart muscle cells. Read More |
Current News
Sunday, May 30th, 2010
Phase 2 Clinical Trial Data Show Significant Improvements in Outcomes and Symptoms in Advanced Heart Failure Patients Treated with Celladon’s Genetically Targeted Enzyme Replacement Therapy MYDICAR®
Wednesday, April 28th, 2010
Celladon Corp. Announces that MYDICAR® Meets Primary Endpoint in Phase 2 Trial for Treatment of Advanced Heart Failure